难治性-话题@MedSci - williamhill asia

#难治性#

683篇内容 | 3443人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1528902, encodeId=3dcc1528902bf, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Neurology：难治性局灶性癫痫患者辅助性塞诺巴胺的长期疗效和安全性研究, objectType=article, longId=738700, objectId=3adfe3870050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3adfe3870050, replyNumber=0, likeNumber=52, createdTime=2022-09-10, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3adfe3870050, moduleTitle=Neurology：难治性局灶性癫痫患者辅助性塞诺巴胺的长期疗效和安全性研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3adfe3870050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528901, encodeId=a7221528901d4, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Neurology：氯胺酮治疗新生儿及儿童难治性癫痫持续状态, objectType=article, longId=737595, objectId=98b5e37595ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98b5e37595ab, replyNumber=0, likeNumber=69, createdTime=2022-09-03, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98b5e37595ab, moduleTitle=Neurology：氯胺酮治疗新生儿及儿童难治性癫痫持续状态, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=98b5e37595ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528900, encodeId=ac4015289001c, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=J Clin Oncol：新型双特异性抗体ABBV-383在复发/难治性多发性骨髓瘤中初显疗效, objectType=article, longId=737430, objectId=dbc4e37430eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbc4e37430eb, replyNumber=0, likeNumber=90, createdTime=2022-09-01, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbc4e37430eb, moduleTitle=J Clin Oncol：新型双特异性抗体ABBV-383在复发/难治性多发性骨髓瘤中初显疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=dbc4e37430eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528899, encodeId=466015288992a, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Crit Care：接受ECMO支持的难治性心源性休克患者早期高压氧与死亡率的关系, objectType=article, longId=737152, objectId=f4b4e37152c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4b4e37152c1, replyNumber=0, likeNumber=81, createdTime=2022-08-29, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4b4e37152c1, moduleTitle=Crit Care：接受ECMO支持的难治性心源性休克患者早期高压氧与死亡率的关系, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f4b4e37152c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528897, encodeId=a8dd152889e3f, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Molecular Psychiatry:内侧前脑束上外侧支深部脑刺激治疗难治性抑郁症后的代谢变化与临床反应相关, objectType=article, longId=737022, objectId=768fe3702251, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=768fe3702251, replyNumber=0, likeNumber=63, createdTime=2022-08-27, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=768fe3702251, moduleTitle=Molecular Psychiatry:内侧前脑束上外侧支深部脑刺激治疗难治性抑郁症后的代谢变化与临床反应相关, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=768fe3702251)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528896, encodeId=5077152889617, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=欧盟批准双特异性抗体Tecvayli（teclistamab）治疗成人复发/难治性多发性骨髓瘤（RRMM）, objectType=article, longId=736911, objectId=1981e36911b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1981e36911b5, replyNumber=0, likeNumber=0, createdTime=2022-08-26, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1981e36911b5, moduleTitle=欧盟批准双特异性抗体Tecvayli（teclistamab）治疗成人复发/难治性多发性骨髓瘤（RRMM）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1981e36911b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528895, encodeId=60ad15288952b, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Rheumatology：复发性或难治性SLE缓解诱导后的利妥昔单抗维持治疗, objectType=article, longId=736513, objectId=a3e7e36513f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3e7e36513f0, replyNumber=0, likeNumber=60, createdTime=2022-08-23, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3e7e36513f0, moduleTitle=Rheumatology：复发性或难治性SLE缓解诱导后的利妥昔单抗维持治疗, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a3e7e36513f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528894, encodeId=b04d15288947d, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=J Clin Oncol：埃罗妥珠单抗联合泊马度胺和地塞米松可显著改善复发/难治性多发性骨髓瘤生存预后, objectType=article, longId=736048, objectId=4468e3604828, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4468e3604828, replyNumber=0, likeNumber=75, createdTime=2022-08-18, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4468e3604828, moduleTitle=J Clin Oncol：埃罗妥珠单抗联合泊马度胺和地塞米松可显著改善复发/难治性多发性骨髓瘤生存预后, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=4468e3604828)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528893, encodeId=b70f152889324, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Rheumatology：低剂量利妥昔单抗对难治性特发性炎性肌病有效, objectType=article, longId=735901, objectId=367be3590160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=367be3590160, replyNumber=0, likeNumber=56, createdTime=2022-08-16, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=367be3590160, moduleTitle=Rheumatology：低剂量利妥昔单抗对难治性特发性炎性肌病有效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=367be3590160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528892, encodeId=e1cf1528892e0, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=NEJM：Teclistamab治疗复发性/难治性多发性骨髓瘤, objectType=article, longId=735741, objectId=dd07e3574140, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd07e3574140, replyNumber=0, likeNumber=78, createdTime=2022-08-14, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd07e3574140, moduleTitle=NEJM：Teclistamab治疗复发性/难治性多发性骨髓瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=dd07e3574140)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528891, encodeId=73bf1528891f7, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=难治性高血压到底有多难治？一文掌握药物治疗策略, objectType=article, longId=734323, objectId=fbebe3432361, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbebe3432361, replyNumber=0, likeNumber=63, createdTime=2022-08-05, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbebe3432361, moduleTitle=难治性高血压到底有多难治？一文掌握药物治疗策略, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=fbebe3432361)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528890, encodeId=a2dd152889041, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=【精彩直播】难治性抑郁高发？原北大六院王向群院长传授诊疗策略！, objectType=article, longId=733817, objectId=714ce3381742, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=714ce3381742, replyNumber=0, likeNumber=52, createdTime=2022-07-30, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=714ce3381742, moduleTitle=【精彩直播】难治性抑郁高发？原北大六院王向群院长传授诊疗策略！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=714ce3381742)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528889, encodeId=541115288894f, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=掌握这几点，难治性痤疮不再犯难, objectType=article, longId=732949, objectId=1323e3294992, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1323e3294992, replyNumber=0, likeNumber=75, createdTime=2022-07-23, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1323e3294992, moduleTitle=掌握这几点，难治性痤疮不再犯难, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1323e3294992)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528888, encodeId=1f951528888ca, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Lancet Oncol：双抗Mosunetuzumab治疗复发或难治性滤泡性淋巴瘤的疗效, objectType=article, longId=732675, objectId=84ece326750e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84ece326750e, replyNumber=0, likeNumber=73, createdTime=2022-07-19, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84ece326750e, moduleTitle=Lancet Oncol：双抗Mosunetuzumab治疗复发或难治性滤泡性淋巴瘤的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=84ece326750e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528887, encodeId=7e35152888ecf, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Lancet Oncol：Lisocabtagene maraleucel二线治疗难治性/复发性大B细胞淋巴瘤, objectType=article, longId=732664, objectId=82c1e326649a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82c1e326649a, replyNumber=0, likeNumber=66, createdTime=2022-07-19, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82c1e326649a, moduleTitle=Lancet Oncol：Lisocabtagene maraleucel二线治疗难治性/复发性大B细胞淋巴瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=82c1e326649a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528886, encodeId=ab5915288863b, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle= Acta Haematol：阿扎胞苷、维奈托克和曲美替尼在携带 RAS 通路激活突变的复发或难治性 AML 中的 II 期研究结果, objectType=article, longId=731496, objectId=0687e314968e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0687e314968e, replyNumber=0, likeNumber=58, createdTime=2022-07-08, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0687e314968e, moduleTitle= Acta Haematol：阿扎胞苷、维奈托克和曲美替尼在携带 RAS 通路激活突变的复发或难治性 AML 中的 II 期研究结果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0687e314968e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528885, encodeId=b77b1528885a2, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Lancet Neurol：Eptinezumab可有效预防难治性偏头痛, objectType=article, longId=731071, objectId=5b57e31071d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b57e31071d5, replyNumber=0, likeNumber=71, createdTime=2022-07-03, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b57e31071d5, moduleTitle=Lancet Neurol：Eptinezumab可有效预防难治性偏头痛, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5b57e31071d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528884, encodeId=9f67152888498, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Ann Hematol：吉列替尼单药治疗复发/难治性 FLT3 突变急性髓细胞白血病的真实世界研究, objectType=article, longId=730781, objectId=f847e307815e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f847e307815e, replyNumber=0, likeNumber=53, createdTime=2022-06-30, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f847e307815e, moduleTitle=Ann Hematol：吉列替尼单药治疗复发/难治性 FLT3 突变急性髓细胞白血病的真实世界研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f847e307815e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528882, encodeId=bd96152888297, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Clin Cancer Res：氟维司群联合维奈托克治疗CDK4/6抑制剂难治性ER+转移性乳腺癌, objectType=article, longId=730361, objectId=69abe303613d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69abe303613d, replyNumber=0, likeNumber=54, createdTime=2022-06-25, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69abe303613d, moduleTitle=Clin Cancer Res：氟维司群联合维奈托克治疗CDK4/6抑制剂难治性ER+转移性乳腺癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=69abe303613d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528881, encodeId=4f87152888180, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Clin Cancer Res：来那度胺联合R-GDP治疗复发/难治性弥漫性大B细胞淋巴瘤, objectType=article, longId=730251, objectId=bec7e302514e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bec7e302514e, replyNumber=0, likeNumber=63, createdTime=2022-06-24, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bec7e302514e, moduleTitle=Clin Cancer Res：来那度胺联合R-GDP治疗复发/难治性弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=bec7e302514e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

难治性

2020-05-29

freve (审核中...)

前往app查看评论内容

#难治性#

Neurology：难治性局灶性癫痫患者辅助性塞诺巴胺的长期疗效和安全性研究

2022-09-10

freve (审核中...)

前往app查看评论内容

#难治性#

Neurology：氯胺酮治疗新生儿及儿童难治性癫痫持续状态

2022-09-03

freve (审核中...)

前往app查看评论内容

#难治性#

J Clin Oncol：新型双特异性抗体ABBV-383在复发/难治性多发性骨髓瘤中初显疗效

2022-09-01

freve (审核中...)

前往app查看评论内容

#难治性#

Crit Care：接受ECMO支持的难治性心源性休克患者早期高压氧与死亡率的关系

2022-08-29

freve (审核中...)

前往app查看评论内容

#难治性#

Molecular Psychiatry:内侧前脑束上外侧支深部脑刺激治疗难治性抑郁症后的代谢变化与临床反应相关

2022-08-27

freve (审核中...)

前往app查看评论内容

#难治性#

欧盟批准双特异性抗体Tecvayli（teclistamab）治疗成人复发/难治性多发性骨髓瘤（RRMM）

2022-08-26

freve (审核中...)

前往app查看评论内容

#难治性#

Rheumatology：复发性或难治性SLE缓解诱导后的利妥昔单抗维持治疗

2022-08-23

freve (审核中...)

前往app查看评论内容

#难治性#

J Clin Oncol：埃罗妥珠单抗联合泊马度胺和地塞米松可显著改善复发/难治性多发性骨髓瘤生存预后

2022-08-18

freve (审核中...)

前往app查看评论内容

#难治性#

Rheumatology：低剂量利妥昔单抗对难治性特发性炎性肌病有效

2022-08-16

freve (审核中...)

前往app查看评论内容

#难治性#

NEJM：Teclistamab治疗复发性/难治性多发性骨髓瘤

2022-08-14

freve (审核中...)

前往app查看评论内容

#难治性#

难治性高血压到底有多难治？一文掌握药物治疗策略

2022-08-05

freve (审核中...)

前往app查看评论内容

#难治性#

【精彩直播】难治性抑郁高发？原北大六院王向群院长传授诊疗策略！

2022-07-30

freve (审核中...)

前往app查看评论内容

#难治性#

掌握这几点，难治性痤疮不再犯难

2022-07-23

freve (审核中...)

前往app查看评论内容

#难治性#

Lancet Oncol：双抗Mosunetuzumab治疗复发或难治性滤泡性淋巴瘤的疗效

2022-07-19

freve (审核中...)

前往app查看评论内容

#难治性#

Lancet Oncol：Lisocabtagene maraleucel二线治疗难治性/复发性大B细胞淋巴瘤

2022-07-19

freve (审核中...)

前往app查看评论内容

#难治性#

Acta Haematol：阿扎胞苷、维奈托克和曲美替尼在携带 RAS 通路激活突变的复发或难治性 AML 中的 II 期研究结果

2022-07-08

freve (审核中...)

前往app查看评论内容

#难治性#

Lancet Neurol：Eptinezumab可有效预防难治性偏头痛

2022-07-03

freve (审核中...)

前往app查看评论内容

#难治性#

Ann Hematol：吉列替尼单药治疗复发/难治性 FLT3 突变急性髓细胞白血病的真实世界研究

2022-06-30

freve (审核中...)

前往app查看评论内容

#难治性#

Clin Cancer Res：氟维司群联合维奈托克治疗CDK4/6抑制剂难治性ER+转移性乳腺癌

2022-06-25

freve (审核中...)

前往app查看评论内容

#难治性#

Clin Cancer Res：来那度胺联合R-GDP治疗复发/难治性弥漫性大B细胞淋巴瘤

2022-06-24

科室
- - 订阅+
  - 更多科室
工具
服务